Goldman lowers target for Evonik to 20 Sell MarketScreener

NEW YORK (dpa-AFX Broker) – U.S. investment bank Goldman Sachs cut its price target for Evonik from 20.20 to 20.00 euros ahead of first-quarter figures and left its rating at “sell.” Analyst Georgina Fraser lowered her assumption for the chemicals group’s operating profit (Ebitda) this year by one percent in a report published Tuesday. This would be based on lower margins in the Nutrition & Care and Specialty Additives segments./bek/mis Publication of the original study: 03.04.2023 / 18:12 / BST First disclosure of original study: Date not stated in study / Time not stated in study / Time zone not…